TU-2218 is under clinical development by TiumBio and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TU-2218’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TU-2218 overview
NCE-401 (TU-2218, SKI-2218) is under development for the treatment of advanced solid tumors, cervical cancer, cholangiocarcinoma, biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer and idiopathic pulmonary fibrosis. The drug candidate is a new chemical entity. It acts by targeting TGF beta receptor type 1 (ALK5) and VEGFR2. It was under development for the treatment of renal fibrosis. It is administered through oral route.
TiumBio overview
TiumBio is a drug discovery company. The company’s pipeline products include chemical entity based drugs such as NCE401, NCE403, NCE406 and new biopharmaceuticals such as NBP604, NBP611 and NBP. The company develops therapies for the treatment of idiopathic pulmonary fibrosis, endometriosis, uterine fibroids, prostate cancer, type 2 diabetes mellitus, hemophilia and rare diseases. TiumBio is headquartered in Seongnam-si, Gyeonggi-do, Korea.
For a complete picture of TU-2218’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
